ArticlePolymers2025
Synthesis and Characterization of a Novel Cassava Starch-Based Scaffold Biofunctionalized with Decellularized Extracellular Matrix and Isosorbide Dinitrate.
Article in Polymers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to synthesize and characterize cassava starch-based (S) scaffolds functionalized with decellularized extracellular matrix (dECM) and isosorbide dinitrate (ISDN) for wound healing. The scaffolds were synthesized via the casting method and evaluated for physicochemical, mechanical, and morphological properties, as well as ISDN release and hemocompatibility. Swelling and degradation tests revealed a biphasic behavior, with high water absorption followed by controlled degradation. The ISDN release followed a biphasic pattern, fitting the Korsmeyer-Peppas model. Hemolysis tests confirmed biocompatibility, with hemolysis levels below 2%. Among the formulations, the scaffold containing 12.5% ECM and 40 mg ISDN exhibited optimal mechanical stability, controlled drug release, and biocompatibility. These findings suggest that starch/ECM/ISDN scaffolds hold potential for wound healing applications. Further studies should focus on in vivo evaluation and cytotoxicity assessments to confirm their clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.